• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Prolonged Presence of SARS-CoV-2 in a COVID-19 Case With Rheumatoid Arthritis Taking Iguratimod Treated With Ciclesonide

tetano

tetano

Editor, Senior Moderator
J Infect Chemother


. 2020 Jul 1;S1341-321X(20)30213-0.
doi: 10.1016/j.jiac.2020.06.022. Online ahead of print.
Prolonged Presence of SARS-CoV-2 in a COVID-19 Case With Rheumatoid Arthritis Taking Iguratimod Treated With Ciclesonide


Hiroaki Baba[SUP] 1 [/SUP], Hajime Kanamori[SUP] 2 [/SUP], Kengo Oshima[SUP] 3 [/SUP], Issei Seike[SUP] 4 [/SUP], Ikumi Niitsuma-Sugaya[SUP] 4 [/SUP], Kentaro Takei[SUP] 4 [/SUP], Yukio Sato[SUP] 5 [/SUP], Koichi Tokuda[SUP] 2 [/SUP], Tetsuji Aoyagi[SUP] 3 [/SUP]



Affiliations

Abstract

We report a coronavirus disease 2019 (COVID-19) case with rheumatoid arthritis taking iguratimod. The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The effects of disease-modifying antirheumatic drugs (DMARDs) and ciclesonide on clinical course and viral shedding remain unknown and warrant further investigation.

Keywords: Ciclesonide; Coronavirus disease 2019; Iguratimod; Viral shedding.
 
You must log in or register to reply here.
Back
Top Bottom